Tables
- TABLE 1
Summary of some of the presentations from the session “ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension”
Study name [ref.] Population Intervention Comparison Primary/secondary outcomes Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) [26] Progressive fibrosing ILD Pirfenidone
24 weeksPlacebo Stopped due to low recruitment; lower FVC decline in treatment arm when applying pre-specified imputation, but not without Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD [3] Progressive fibrosing unclassifiable ILD Pirfenidone
24 weeksPlacebo Primary end-point (FVC change by home spirometry) was not assessed due to technical problems; lower FVC decrease in treatment arm in site spirometry Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial [25] Progressive fibrosing ILD Nintedanib
52 weeksPlacebo Lower adjusted annual rate of decline in FVC (mL·year−1) Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) [27] Systemic sclerosis Tocilizumab
48 weeksPlacebo No difference in change in modified Rodnan skin score; lower proportion of patients losing >10% of FVC on the treatment arm Transbronchial lung cryobiopsy for interstitial lung disease diagnosis: results of the COLDICE Study [28] ILD requiring biopsy Transbronchial lung cryobiopsy Surgical lung biopsy High level of agreement between both types of biopsy IPF: idiopathic pulmonary fibrosis; ILD: interstitial lung disease; FVC: forced vital capacity.
Vol 6 Issue 4
Table of Contents
ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly
